lava-051
lava therapeutics
['lava-051 ', 'lavatx', 'lava therapeutics']
tomorrow at #asco22, arnon kater, m.d., ph.d., will present initial dose-escalation data from our lava-051 phase 1/2a clinical trial using our #gammabody platform in patients with certain hematologic #cancers. learn more: #immunooncology 
Immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to treat cancer.